文献速递免疫规划卫生政策与健康促进

国际制药商协会联合会流感疫苗供应国际工作组2022-2023年季节性流感疫苗剂量分发调查:证据表明需要各国承诺投资并提升季节性流感疫苗接种

The IFPMA IVS seasonal influenza vaccine dose distribution survey 2022-2023: evidence of the need for committed national investment in and uptake of seasonal influenza vaccination.
PubMed 文献 · Vaccine · 2025-09-21

国际制药商协会联合会流感疫苗供应国际工作组调查显示,2020和2021年季节性流感疫苗接种覆盖率的大幅提升未能持续。2022年分发任何剂量疫苗的国家比2011年峰值少27个,2023年少29个;2023年全球分发剂量比2020年峰值少17%。195个国家中仅33个在2023年达到门槛率(向≥15.9%人口分发剂量)。

要点

  • 2022和2023年季节性流感疫苗接种覆盖率未能维持2020和2021年的大幅提升。
  • 2023年全球分发剂量比2020年峰值少17%,仅33/195国达到≥15.9%人口分发剂量的门槛率。
  • 免疫接种社会价值回报高达成本的19倍,政府需采取疫苗倡导、沟通和医护人员沟通培训等对策。

核心结论

  • 2020和2021年季节性流感疫苗接种覆盖率的大幅提升未能持续,2022和2023年分发疫苗的国家数及全球分发剂量均较峰值下降。
  • 免疫接种的社会价值回报高达成本的19倍,政府需识别并实施针对疫苗犹豫和自满的适当对策。

研究设计与样本

  • 国际制药商协会联合会流感疫苗供应国际工作组于2008年开发调查方法,用于估算疫苗接种覆盖率;本次调查针对2022年和2023年。

主要发现

  • 2022年分发任何季节性流感疫苗剂量的国家比国家数峰值年2011年少27个,2023年少29个。
  • 2023年全球分发的疫苗剂量比峰值年2020年少17%。
  • 2023年195个国家中仅33个达到门槛率,即向≥15.9%的人口分发剂量。

关键数值与推荐

  • 门槛率定义为向≥15.9%的人口分发疫苗剂量。
  • 免疫接种的社会价值回报高达成本的19倍。

临床怎么用

  • 政府可通过若干关键行动加强季节性流感疫苗接种规划的表现。
  • 政府需识别并实施针对疫苗犹豫和自满的适当对策,包括疫苗倡导、沟通以及医护人员的沟通培训。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Seasonal influenza vaccines have the potential to prevent significant morbidity and mortality and the World Health Organization recommends that all countries consider implementing seasonal influenza immunization programmes. These provide invaluable supports to pandemic response, whether through the utilization of influenza epidemiological surveillance systems such as the WHO Global Influenza Surveillance and Response System (GISRS) or RespiMart, by imparting countries with ability to scale up vaccination in response to pandemics, and by contributing to the global production capacity for vaccines. During the COVID-19 pandemic, countries with higher influenza vaccination coverage also achieved higher COVID-19 vaccination coverage. But vaccine hesitancy and complacency are preventing optimal benefits from seasonal influenza vaccination. In 2008, the International Federation of Pharmaceutical Manufacturers and Associations' (IFPMA) Influenza Vaccine Supply International Task Force (IVS) developed a survey method to estimate vaccination coverage rates. The present survey, for 2022 and 2023, highlights that the vast improvements in seasonal influenza vaccination coverage rates achieved during 2020 and 2021 are regrettably not being sustained. Twenty-seven fewer countries in 2022 and 29 fewer countries in 2023 distributed any doses of seasonal influenza than in the peak year for number of countries, 2011. In 2023 there were 17 % fewer vaccine doses distributed globally than in the peak year, 2020. Only 33 of 195 countries achieved the hurdle rate in 2023, defined as number of doses distributed to ≥15.9 % of the population. Governments can strengthen performance of their seasonal influenza vaccination programs with a few key actions. Because immunization returns up to 19 times the cost in societal value, it is critical for governments to identify and implement appropriate countermeasures to vaccine hesitancy and complacency including vaccine advocacy, communications, and communication training for Healthcare Workers. Governments' challenge is to sustain resolve beyond the public health emergency of COVID-19.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Palache B, Fyyaz H, Thomson D, et al. The IFPMA IVS seasonal influenza vaccine dose distribution survey 2022-2023: evidence of the need for committed national investment in and uptake of seasonal influenza vaccination. Vaccine. 2025. PMID: 40983024. doi:10.1016/j.vaccine.2025.127747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。